In utero CRISPR-mediated therapeutic editing of metabolic genes

[1]  W. Harrington,et al.  A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. , 2018, Cell reports.

[2]  T. Walters,et al.  Co-delivery of a laminin-111 supplemented hyaluronic acid based hydrogel with minced muscle graft in the treatment of volumetric muscle loss injury , 2018, PloS one.

[3]  Daniel G. Anderson,et al.  Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing , 2017, Nature Biotechnology.

[4]  Kiran Musunuru,et al.  In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[5]  Daesik Kim,et al.  Genome-wide target specificities of CRISPR RNA-guided programmable deaminases , 2017, Nature Biotechnology.

[6]  David A. Brafman,et al.  The Impact of Chromatin Dynamics on Cas9-Mediated Genome Editing in Human Cells. , 2017, ACS synthetic biology.

[7]  E. Olson,et al.  Notch Inhibition Enhances Cardiac Reprogramming by Increasing MEF2C Transcriptional Activity , 2017, Stem cell reports.

[8]  Kevin T. Zhao,et al.  Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions , 2017, Nature Biotechnology.

[9]  A. Flake,et al.  Induction of Immune Tolerance to Foreign Protein via Adeno-Associated Viral Vector Gene Transfer in Mid-Gestation Fetal Sheep , 2017, PloS one.

[10]  Pavel Sumazin,et al.  Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia , 2016, Nature Communications.

[11]  J. Joly,et al.  Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR , 2016, Genome Biology.

[12]  A. Flake,et al.  The Intravenous Route of Injection Optimizes Engraftment and Survival in the Murine Model of In Utero Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  David R. Liu,et al.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.

[14]  S. Ghaffari,et al.  Prenatal Diagnosis of Tyrosinemia Type 1 Using Next Generation Sequencing , 2016, Fetal and pediatric pathology.

[15]  Kiran Musunuru,et al.  CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo—Brief Report , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Yang Yang,et al.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice , 2016, Nature Biotechnology.

[17]  Daniel G. Anderson,et al.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.

[18]  Zhiping Weng,et al.  Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. , 2015, Human gene therapy.

[19]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[20]  Daniel J. Rader,et al.  Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing , 2014, Circulation research.

[21]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[22]  W. Pu,et al.  Peritruncal Coronary Endothelial Cells Contribute to Proximal Coronary Artery Stems and Their Aortic Orifices in the Mouse Heart , 2013, PloS one.

[23]  Felipe Ortega,et al.  Oligodendrogliogenic and neurogenic adult subependymal zone neural stem cells constitute distinct lineages and exhibit differential responsiveness to Wnt signalling , 2013, Nature Cell Biology.

[24]  J. Epstein,et al.  Hopx expression defines a subset of multipotent hair follicle stem cells and a progenitor population primed to give rise to K6+ niche cells , 2013, Development.

[25]  S. Mittal,et al.  Adenoviral vector immunity: its implications and circumvention strategies. , 2011, Current gene therapy.

[26]  M. Kay,et al.  Adeno‐associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo , 2010, Hepatology.

[27]  K. High,et al.  Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Thomas Ferkol,et al.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. , 2007, Human gene therapy.

[29]  Aarati R. Ranade,et al.  Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice , 2007, Nature Biotechnology.

[30]  Marcela V Maus,et al.  CD8+ T-cell responses to adeno-associated virus capsid in humans , 2007, Nature Medicine.

[31]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[32]  M. Dallman,et al.  In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. , 2003, Blood.

[33]  L. Hauser,et al.  Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Lipshutz,et al.  Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  G. Morrow,et al.  Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1. , 2017, Advances in experimental medicine and biology.

[36]  P. Zoltick,et al.  The developmental stage determines the distribution and duration of gene expression after early intra-amniotic gene transfer using lentiviral vectors , 2010, Gene Therapy.